The glyceraldehyde dehydrogenase from Thermoplasma acidophilum (TaAlDH) is a microbial enzyme that catalyzes the oxidation of d-glyceraldehyde to d-glycerate in the artificial enzyme cascade designed for the conversion of glucose to the organic solvents isobutanol and ethanol. Various mutants of TaAlDH were constructed by a random approach followed by site-directed and saturation mutagenesis in order to improve the properties of the enzyme that are essential for its functioning within the cascade. Two enzyme variants, wild-type TaAlDH (TaAlDHwt) and an F34M+S405N variant (TaAlDH F34M+S405N), were successfully crystallized. Crystals of TaAlDHwt belonged to the monoclinic space group P12 1 1 with eight molecules per asymmetric unit and diffracted to a resolution of 1.95 Å . TaAlDH F34M+S405N crystallized in two different space groups: triclinic P1 with 16 molecules per asymmetric unit and monoclinic C121 with four molecules per asymmetric unit. These crystals diffracted to resolutions of 2.14 and 2.10 Å for the P1 and C121 crystals, respectively.
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Introduction
The biotechnological production of chemical compounds from natural regenerative resources is environmentally gentler compared with chemocatalytical fabrication processes from fossil resources (Farrell et al., 2006; Morris & Ahmed, 1993; Zhang et al., 2007; Rupp, 2013) . In terms of bioproduction, cell-free processes are more effective than microbial production techniques since enzymes can tolerate higher temperatures and concentrations of final product than cells (Guterl et al., 2012; Lopez-Gallego & Schmidt-Dannert, 2010; . To date, artificial cell-free enzyme cascades have been developed for the bioproduction of hydrogen (Zhang et al., 2007; Ye et al., 2009 ) and ethanol (Algar & Scopes, 1985; Welch & Scopes, 1985) .
Recently, a system for the enzymatic conversion of glucose to isobutanol and ethanol has been described (Guterl et al., 2012) . The enzymes used in this artificial cascade tolerate organic solvents at high concentrations; the enzymatic ensemble showed high activity in the presence of up to 4% isobutanol. The oxidation of d-glyceraldehyde to d-glycerate is a key reaction in this synthetic pathway. The reaction is catalyzed by glyceraldehyde dehydrogenase (AlDH), which ideally combines the following properties for functioning within the cascade: high thermostability and tolerance towards the solvent, high activity, acceptance of NAD + as cofactor and high substrate specificity . The glyceraldehyde dehydrogenase from Thermoplasma acidophilum (TaAlDH) has a high substrate specificity compared with other AlDHs, which makes TaAlDH a good candidate for the cell-free synthesis of ethanol and isobutanol, although it requires some optimization (Guterl et al., 2012; Jung & Lee, 2006; Reher & Schö nheit, 2006) . Recombinant TaAlDHwt produced in Escherichia coli is mainly insoluble and has a comparatively poor affinity for the cofactor NAD + (K m = 22.7 mM, k cat = 1.64 s À1 ; and a low activity towards glyceraldehyde (2.0 U mg À1 ). TaAlDH was found to function at an isobutanol concentration of up to 9%. Although such a concentration of the solvent is already higher than the microbial tolerance limit, it is desirable to increase the enzyme stability towards isobutanol and ethanol, preferably up to the concentration at which phase separation occurs (about 12%; .
The properties of the enzyme were optimized by a directed evolution approach . The F34M+S405N variant showed an overall 8.5-fold increase in volumetric activity, a slight increase in NAD + acceptance and a ninefold improvement in catalytic efficiency with NAD + compared with the wild type (K m = 17.6 mM, k cat = 10.99 s À1 ). Neither a significant increase in solvent tolerance nor an enhancement of solubility was observed for this mutant .
For further improvement of TaAlDH, it will be more effective to modify the enzyme at target positions via rational design. Since the available TaAlDH protein models are poor (homology of <40%), a TaAlDH crystal structure would allow distinct enzyme modifications with a predictable impact on activity and stability. In this paper, crystallization and initial X-ray diffraction analysis of wild-type TaAlDH (TaAlDHwt) and the F34M+S405N variant (TaAlDH F34M+S405N) are reported.
Materials and methods

Protein preparation
The gene sequence for the glyceraldehyde dehydrogenase from T. acidophilum (taaldh) was translated from the protein sequence (NCBI accession No. CAC11938.1), codonoptimized for expression in E. coli and provided by GeneArt, Regensburg, Germany. The expression vector for the production of TaAlDHwt was constructed according to Guterl et al. (2012) (Table 1) . TaAlDHwt was produced and purified as described previously . After fedbatch fermentation of pCBRHisC-taaldh-transformed E. coli cells, cell lysis and fractionation, TaAlDH was refolded from insoluble inclusion bodies . For this, TaAlDHwt inclusion bodies were purified and dissolved in 6 M guanidinium chloride containing 2 mM dithiothreitol and Tris pH 8.0. Completely unfolded TaAlDHwt was bound to nickel-agarose in a HisTrap FF column (GE Healthcare, Germany) and refolded in vitro by dilution of the guanidinium chloride to native conditions using Tris pH 8.0 with 0.5 M NaCl and 20%(v/v) glycerol. After elution from the column and a further buffer exchange, refolded TaAlDHwt was lyophilized in 20 mM NH 4 HCO 3 using an Alpha 2-4 LD Plus freeze dryer (Martin Christ, Germany). 
Reverse primers TaAlDH_rev The expression vector for the production of TaAlDH F34M+S405N was constructed according to . Forward and reverse primers were applied for the insertion of DNA triplets into pCBRHisC-taaldh via a modified QuikChange protocol according to Wang & Malcolm (1999) (Table 1) . TaAlDH F34M+S405N was produced and purified as described previously . Large amounts of expression culture were used for the downstream processing of TaAlDH F34M+S405N to compensate for the low target-protein solubility.
The theoretical mass of the protein was determined with the Compute pI/Mw tool provided by the SIB Swiss Institute of Bioinformatics (Gasteiger et al., 2005) .
All chemicals were of analytical grade and were purchased from Sigma-Aldrich (Taufkirchen, Germany), Carl Roth GmbH (Karlsruhe, Germany), Serva Electrophoresis GmbH (Heidelberg, Germany), Merck KGaA (Darmstadt, Germany), New England Biolabs (Frankfurt, Germany) or Thermo Fisher Scientific (Ulm, Germany).
Crystallization
Prior to crystallization trials, the lyophilized enzyme was dissolved in 100 mM HEPES buffer pH 7.5 to concentrations of 2-13 mg ml À1 without the addition of cofactor. The initial screening for crystallization conditions was carried out using a Gryphon crystallization robot (Art Robbins Instruments, USA) by the sitting-drop vapour-diffusion method in MRC 2-well crystallization plates (Hampton Research, USA). Freshly prepared protein solution was mixed with 0.2 ml reservoir solution in 1:1 and 2:1 ratios and equilibrated against 70 ml reservoir solution at 295 K. For the initial screening of crystallization conditions, various commercial screens were applied, such as Morpheus (Molecular Dimensions), The PEGs Suite (Qiagen, The Netherlands), Index (Hampton Research, USA), Structure Screen 1 + 2 (Molecular Dimensions), PACT premier (Molecular Dimensions), The PGA Screen (Molecular Dimensions) and PEGRx (Hampton Research, USA). The obtained crystallization conditions were optimized by variation of the pH and the protein and precipitant concentrations and ratios, the use of various additives and a microseeding procedure (Bergfors, 1999) . Optimization experiments were carried out by the sitting-drop vapourdiffusion method in 24-well CombiClover crystallization plates (Jena Bioscience GmbH, Germany) at 295 K. Droplets of 1-3 ml protein solution were mixed with reservoir solution in ratios of 1:1, 2:1, 1:2 and 3:2 and were equilibrated against 800 ml reservoir solution. For the preparation of seed stocks, crystals of the protein were transferred with a nylon loop (Hampton Research, USA) into a 50 ml drop of reservoir solution and crushed into microseeds using a Seed Bead (Hampton Research, USA) followed by serial dilutions of 1:10 to 1:100 000. In microseeding experiments, 1 ml seed stock was pipetted into a drop consisting of 1-4 ml protein solution at a concentration of 2 or 4 mg ml À1 and the reservoir solution in ratios of 1:1, 2:3, 3:2 and 4:1. The identity of the crystallized protein was checked by Coomassie Blue staining of a 12% SDS-PAGE gel using ColorBurst Electrophoresis Marker MW 8-220 kDa (Sigma-Aldrich, USA; see Fig. 2c ). The diffraction data for all crystals were processed using the XDSAPP graphical user interface (Krug et al., 2012) to run XDS (Kabsch, 2010) . The solvent content of the crystals was analyzed by calculation of the Matthews coefficient (Matthews, 1968) for all data sets using MATTHEWS_COEF from the CCP4 package (Winn et al., 2011) . Complete data-collection statistics for all data sets are summarized in Table 2. 3. Results and discussion 3.1. TaAlDHwt Initial screening for crystallization conditions of TaAlDHwt was performed using various commercial screens at room temperature. Different types of crystals grew within 1-2 weeks after initial screening in 30 diverse conditions at a protein concentration of 10.5 mg ml À1 . Microcrystals were found in five different conditions (No. 36 of PEGRx, F10 of Morpheus and B12, C9 and E4 of Structure Screen 1 + 2), plate-like crystals in nine different conditions (A11 and E10 of PACT premier, Nos. 65, 78 and 95 of PEGRx and B6, D2, E2 and E3 of Morpheus) and needles in four conditions (B6 of The PGA Screen and Nos. 54, 58 and 84 of PEGRx); three-dimensional crystals that were mostly rounded in shape appeared in 12 conditions (B2, E10, F2, F3, F6, G2, H2, H3, H6 and H7 of Morpheus, F7 of Structure Screen 1 + 2 and No. 61 of Index) ( Figs. 1a-1e ). These crystallization conditions included a wide range of salts, PEGs, types of buffers, pH values and additives; thus, no pattern in the crystallization behaviour of TaAlDHwt was found.
X-ray diffraction data collection and processing
Diffracting crystals of TaAlDHwt grew in one week after initial screening to dimensions of about 0.02 Â 0.08 Â 0.1 mm in condition H6 of the Morpheus screen using a protein: precipitant ratio of 1:1. The precipitant cocktail consisted of 50 mM MOPS, 50 mM sodium HEPES pH 7.5, 20%(v/v) ethylene glycol, 10%(w/v) PEG 8000, 20 mM glutamic acid (racemic), 20 mM glycine, 20 mM serine (racemic), 20 mM alanine (racemic), 20 mM lysine-HCl (racemic). These crystals diffracted to 2.53 Å resolution.
In order to obtain the best-quality crystals, optimization was carried out considering the following parameters: (i) the already known diffraction quality of the crystals, (ii) the size and shape of the crystals (large single crystals with sharp edges are preferred) and (iii) visually different crystal forms (to check as many different variants of protein-molecule packing inside the crystal as possible). According to these rules, several crystallization conditions were selected for optimization based on the results of initial screening. These conditions included H6 of Morpheus, which produced a crystal that diffracted to 2.53 Å resolution after initial screening, D2 of Morpheus, which resulted in the growth of a large single crystal with sharp edges, No. 95 of PEGRx, which gave crystals of a nice rhombic shape, and No. 84 of PEGRx, from which another crystal form consisting of needles grew. Optimization, including variation of the pH and the protein and precipitant concentrations and ratios, resulted in adequate crystal quality only for condition H6 of Morpheus. The crystals from the other conditions were poorly reproducible and only diffracted to 8-10 Å resolution even after the microseeding procedure.
Optimization of crystallization showed that the best crystals grew using the same precipitant cocktail composition as in the initial screening, but with a larger drop volume of 3 ml, a protein:precipitant ratio of 2:1 and a protein concentration of 9.6 mg ml À1 (Fig. 2a) . The crystals diffracted X-rays to 1.95 Å resolution and belonged to space group P2 1 , with unit-cell parameters a = 95.29, b = 152.35, c = 149.90 Å , = = 90.0, = 92.19 (Fig. 3a) . According to Matthews coefficient calculations (V M = 2.41 Å 3 Da À1 ), these crystals contained eight molecules in the asymmetric unit with a solvent content of 48.95%.
TaAlDH F34M+S405N
Initial screening for crystallization conditions of TaAlDH F34M+S405N at a concentration of 13 mg ml À1 revealed variously shaped three-dimensional crystals in 24 different conditions: Nos. 1, 2 and 3 of The PEGs Suite, C2, G2, H2, H3, H6 and H7 of Morpheus, Nos. 3, 4, 5, 6, 17, 26, 30, 32 and 35 of Index and A6, C6, E11, F2, F11 and G1 of Structure Screen 1 + 2 (Figs. 1f, 1g and 1h ). Conditions G2 of Morpheus and No. 1 of The PEGs Suite were selected for optimization using the same strategy as used for the crystals of TaAlDHwt. Good results were obtained for the crystals from condition G2 of Morpheus after variation of the pH and the protein and precipitant concentrations. The final composition of the precipitant consisted of 50 mM MES, 50 mM imidazole pH 6.5, 8.3%(w/v) PEG 8000, 16.7%(v/v) ethylene glycol, 20 mM sodium formate, 20 mM sodium citrate, 20 mM sodium oxamate, 20 mM ammonium acetate, 20 mM sodium potassium tartrate (for crystal form A). The crystals reached final dimensions of 0.08 Â 0.1 Â 0.7 mm after 5 d of incubation (Fig. 2b) . These crystals diffracted to 2.14 Å resolution and belonged to the triclinic space group P1 (Fig. 3b) . The unit-cell parameters were a = 92.30, b = 157.99, c = 158.00 Å , = 73.1, = 81.8, = 83.8 . The most probable Matthews coefficient (V M = 2.4 Å 3 Da À1 ) corresponds to the presence of 16 molecules in the asymmetric unit, with a solvent content of 49.05%.
Another crystal form of TaAlDH F34M+S405N (crystal form B) was found in condition No. 1 of The PEGs Suite (Fig. 1h ). The crystals grew to dimensions of 0.05 Â 0.1 Â 0.1 mm after two weeks in a precipitant cocktail consisting of 0.1 M sodium acetate pH 4.6, 40%(v/v) PEG 200. Optimization did not yield any improvement in the quality of the crystals, and diffraction data were collected from crystals from the initial screening. The resolution of the diffraction data was 2.1 Å ; the crystals belonged to the monoclinic space group C2, with unit-cell parameters a = 108.1, b = 158.4, c = 130.1 Å , = = 90, = 91.6 (Fig. 3c ). The Matthews coefficient (V M = 2.5 Å 3 Da À1 ) suggests the presence of four molecules in the asymmetric unit, with a solvent content of 50.47%.
Structure determination of TaAlDHwt and TaAlDH F34M+S405N by molecular replacement using the coordinates of betaine-aldehyde dehydrogenase from Pseudoalteromonas atlantica T6c (38% sequence identity; PDB entry 3k2w; New York SGX Research Center for Structural Genomics, unpublished work) as a model is currently in progress. Structural characterization of TaAlDHwt and its mutant will facilitate the determination of the structural features responsible for the activity, specificity and stability of the enzyme.
